<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02085473</url>
  </required_header>
  <id_info>
    <org_study_id>D2210C00011</org_study_id>
    <nct_id>NCT02085473</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the pharmacokinetics and tolerability of  tralokinumab
      when delivered at different flow rates to healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of tralokinumab</measure>
    <time_frame>Day 1,2,4,6,8,10,15,22,36,57</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity, measured using 100mm Visual Analogue Scale (VAS)</measure>
    <time_frame>Day 1 to 57</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injection site reactions</measure>
    <time_frame>Day 1 to 57</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections at flow rate 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection at flow rate 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection at flow rate 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection at flow rate 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Subcutaneous Injection</intervention_name>
    <description>Subcutaneous Injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy males and females ages 19-65 years

          -  Body mass index of 19.0-30.0 kg/m2

          -  No clinically significant abnormality

          -  Vital signs, electrocardiogram (ECG), and laboratory parameters within normal range

          -  Negative alcohol and drug screens

          -  Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use highly effective contraception

          -  Nonsterilized males who are sexually active with a female partner of childbearing
             potential must use highly effective contraception

        Key Exclusion Criteria:

          -  Concurrent enrollment in another clinical study where the subject is receiving an
             investigational product

          -  Receipt of any marketed or investigational biologic agent within 4 months or 5
             half-lives prior to screening, whichever is longer

          -  Receipt of any investigational nonbiologic agent within 3 months or 5 half-lives
             prior to screening, whichever is longer

          -  Current use of regular pain-modifying, anti-depressant, anxiolytic, or hypnotic
             medication

          -  History of thrombocytopenia or bleeding disorder or use of anticoagulants

          -  History of any immunodeficiency disorder or use of immunosuppressive medication.

          -  History of a clinically significant infection

          -  History of cancer

          -  Hepatitis B or C
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Cook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MedImmune Contact</last_name>
    <email>ClinicalTrialEnquiries@Medimmune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
